Should clinical trials about prostate cancer assess the frailty as an endpoint?

被引：0
|
作者：
Irfan Karahan
Didem Sener Dede
机构：
[1] Ankara Bilkent City Hospital,Department of Medical Oncology
[2] Ankara Yildirim Beyazıt University,undefined
来源：
International Urology and Nephrology | 2023年 / 55卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1729 / 1730
页数：1
相关论文
共 50 条
  • [41] Why should cancer patients participate in clinical trials?
    Markman, M
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 1998, 65 (09) : 497 - 499
  • [42] Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?
    Sarah A. Holstein
    Vera J. Suman
    Philip L. McCarthy
    Current Hematologic Malignancy Reports, 2019, 14 : 31 - 38
  • [43] Should MRI be the primary endpoint of phase III trials in MS? No
    Weinshenker, B. G.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 28 - 28
  • [44] Functional imaging in drug development - a primary or secondary endpoint in cancer clinical trials
    Sullivan, D. C.
    EJC SUPPLEMENTS, 2006, 4 (12): : 8 - 8
  • [45] Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?
    Holstein, Sarah A.
    Suman, Vera J.
    McCarthy, Philip L.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2019, 14 (01) : 31 - 38
  • [46] Department of Defense Prostate Cancer Clinical Trials Consortium: A New Instrument for Prostate Cancer Clinical Research
    Morris, Michael J.
    Basch, Ethan M.
    Wilding, George
    Hussain, Maha
    Carducci, Michael A.
    Higano, Celestia
    Kantoff, Philip
    Oh, William K.
    Small, Eric J.
    George, Daniel
    Mathew, Paul
    Beer, Tomaz M.
    Slovin, Susan F.
    Ryan, Charles
    Logothetis, Christopher
    Scher, Howard I.
    CLINICAL GENITOURINARY CANCER, 2009, 7 (01) : 51 - 57
  • [47] Should the LIFE Trial Assess Improvement in Ejection Fraction as a Primary Endpoint?
    Simon, Steny
    Mandal, Amit K. J.
    Missouris, Constantinos G.
    JACC-HEART FAILURE, 2020, 8 (11) : 959 - 960
  • [48] Consistency as an endpoint in migraine clinical trials.
    Lipton, RB
    CEPHALALGIA, 1999, 19 (04) : 273 - 273
  • [49] Innovative Thinking on Endpoint Selection in Clinical Trials
    Chow, Shein-Chung
    Huang, Zhipeng
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2019, 29 (05) : 941 - 951
  • [50] How should we assess randomised trials?
    Chen, Patrick
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2023, 130 (07) : 693 - 694
12345